Amicus Therapeutics (FOLD) has been quietly rewarding patient holders, with the stock climbing around 44% over the past month and more than 70% in the past 3 months, outpacing many biotech peers. See ...
We were overwhelmed by the response to our annual Letters to Santa feature, with more than 1,250 letters submitted this year. Due ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback